(Q43001311)

English

HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin

scientific article published in November 2000

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

author name string

T Carlsson

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

K Lindahl

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

R Schvarcz

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

R Wejstal

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

I Uhnoo

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

S Shev

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

O Reichard

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

1 November 2000

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

409-413

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00256.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00256.X

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00256.X

21 January 2018

ANTIVIRAL ACTIVITY OF 1-ADAMANTANAMINE (AMANTADINE).

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00256.X

21 January 2018

On the Mechanism of Inhibition of Influenza Virus Replication by Amantadine Hydrochloride

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00256.X

21 January 2018

Inhibition of dengue virus replication by amantadine hydrochloride

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00256.X

21 January 2018

Cytokeratin expression is reduced in glycogenotic clear hepatocytes but increased in ground-glass cells in chronic human and woodchuck hepadnaviral infection

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00256.X

21 January 2018

Histological and virological long-term outcome in patients treated with interferon-alpha2b and ribavirin for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00256.X

21 January 2018

Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00256.X

21 January 2018

In vitro effect of amantadine and interferon alpha-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00256.X

21 January 2018

Amantadine and rimantadine have no direct inhibitory effects against hepatitis C viral protease, helicase, ATPase, polymerase, and internal ribosomal entry site-mediated translation

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2000.00256.X

21 January 2018

Identifiers

10.1046/J.1365-2893.2000.00256.X

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43001311&oldid=1976342350"